Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | OBX-115 |
| Synonyms | |
| Therapy Description |
OBX-115 comprises tumor-infiltrating lymphocytes (TILs) engineered to express membrane-bound IL-15 (mbIL15), which potentially induce tumor cell killing and lead to antitumor activity (J Clin Oncol 42, 2024 (suppl 16; abstr 9515), NCI Drug Dictionary). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| OBX-115 | OBX 115|OBX115|CytoTIL15 | OBX-115 comprises tumor-infiltrating lymphocytes (TILs) engineered to express membrane-bound IL-15 (mbIL15), which potentially induce tumor cell killing and lead to antitumor activity (J Clin Oncol 42, 2024 (suppl 16; abstr 9515), NCI Drug Dictionary). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT06060613 | Phase Ib/II | OBX-115 | Safety and Efficacy of OBX-115 in Advanced Solid Tumors | Recruiting | USA | 0 |